Expression Therapeutics, Inc. is at the forefront of developing innovative gene and cell therapies aimed at treating severe genetic diseases in both children and adults. The company employs advanced transgene bioengineering and protein engineering techniques to tailor gene therapies for specific conditions, including bleeding disorders, primary immunodeficiencies, and various cancers. Their clinical programs utilize both lentiviral (LV) vectors and adeno-associated viral (AAV) vectors, reflecting a multi-platform approach that allows for flexibility in drug development without being limited to a single technology.

In the realm of oncology, Expression Therapeutics leverages proprietary non-signaling chimeric antigen receptor technology to enhance the targeting capabilities of gamma delta T cells. This approach addresses potential issues related to long-term T cell ablation and tonic signaling, facilitating the development of allogeneic cell therapies for conditions such as neuroblastoma, T cell leukemia, lymphoma, and acute myeloid leukemia. Additionally, the company boasts a state-of-the-art manufacturing facility that spans 43,000 square feet, designed to produce cGMP-compliant LV and AAV vectors, cell therapy products, and recombinant proteins, thereby accelerating the advancement of their clinical programs.

United States

Expression Therapeutics, Inc. is a fully integrated clinical stage gene and cell therapy company developing novel, potentially curative, therapeutics for hematology and oncology. The Company, based in Atlanta, Georgia, has a state-of-the-art 43,000 square foot manufacturing facility in West Chester, Ohio.

Expression Therapeutics, Inc. also built a state-of-the-art scalable 43,000 square foot manufacturing facility in Cincinnati, Ohio.

Expression Therapeutics

Company Details